FUL.L Regulatory News (FUL)

25 Jan 2005 07:00

Fulcrum Pharma PLC25 January 2005 For immediate release 25 January 2005 Fulcrum Pharma plc ("Fulcrum" or "the Company") Fulcrum to present at BioBusiness 2005 with Addex Pharmaceuticals Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcingservices company, announces today that its CEO, Dr Jon Court, will beco-presenting with the CEO of Addex Pharmaceuticals, Vincent Mutel, at theBioBusiness 2005 bio-partnering event on Wednesday 26th January 2005 at 14:30 atthe President Wilson Hotel, Geneva. The presentation will be entitled 'Networked Drug Development: The New WayForward'. During the presentation Addex and Fulcrum will discuss the benefits of workingtogether and of using a drug development services company to optimise and managecustomer development services. Fulcrum discusses the merits of its strategy forincreasing the probability of success through giving faster and more costeffective delivery of drug development programmes. In 2003, Fulcrum announced that it had signed a preferred supplier arrangementwith Addex, the Swiss pharmaceutical company focused on central nervous systemdisorders, whereby Fulcrum would take an equity stake in Addex and receive feesfor service over a three year period. In return Fulcrum would provide drugdevelopment services for the Addex portfolio of novel compounds. Dr Jon Court, CEO of Fulcrum Pharma, said: "We are extremely pleased with thesuccess of our development partnership with Addex. Our presence at thisconference not only validates our partnership and investment with Addex but alsoour business strategy. "We were pleased to note the recent collaboration and licence agreement thatAddex signed with Ortho-McNeil Pharmaceutical, a Johnson & Johnson company, inthe area of CNS and look forward to our involvement to support thatcollaboration." For further information, please contact: Fulcrum Pharma PLC Tel: 0870 710 7152Jon Court, CEO Buchanan Communications Tel: 020 7466 5000Mary-Jane Johnson Notes to Editors: About Fulcrum Pharma Fulcrum Pharma plc is an independent, drug development company that is the firstto offer global virtual drug development and strategic outsourcing services tothe pharmaceutical industry. The Company has expertise in the design, executionand delivery of drug development programmes and relies on state of the artinformation technology and infrastructure in the supply of its services. Through Fulcrum's services to its clients, the Directors believe that there isthe capacity to deliver products faster and more efficiently to the globalpharmaceutical market. Fulcrum does this by using its skills in the design ofdrug programmes that deliver the necessary information for decision-making andproduct registration. In so doing, Fulcrum works closely with its clients tomeet their strategic R&D goals. Fulcrum Pharma is listed on the Alternative Investment Market of the LondonStock Exchange having successfully floated in March 2000. This information is provided by RNS The company news service from the London Stock Exchange